Prot# XRP9881B-3001: Randomized, Open-Label, Phase III Study of RPR109881 IV Every 3 Weeks vs Capecitabine (Xeloda®) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients w/ Metastatic Breast Cancer Progressing after Taxanes & Anthracycli

Project: Research project

Project Details

StatusFinished
Effective start/end date9/23/05 → 11/20/08

Funding

  • Pharmaceutical Product Development, LLC (XRP9881B-3001)
  • Aventis Pharmaceuticals Inc. (XRP9881B-3001)